HDT 2025 Emerging Leader Dylan West built his own driver simulator, created data-driven scorecards, and developed tools that ...

Eliminating Silos with a Unified Security Platform R82.10 expands Check Point’s open-garden architecture with more than 250 integrations. These integrations allow organizations to apply endpoint ...

Abbott’s roughly $21 billion acquisition of cancer screening firm Exact Sciences lays out the company’s future strategy. Analysts said the acquisition not only marks Abbott’s foray into cancer ...

Abbott Laboratories ABT-1.10%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.04%increase; green up pointing triangle in a deal valued at about ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

The acquisition will allow the diagnostics giant to enter the rapidly growing market for cancer tests Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients ...

Abbott Laboratories agreed to acquire cancer diagnostics company Exact Sciences in a deal worth about $21 billion. Exact Sciences shareholders will receive $105 a share. The stock rose 18% to $101.29 ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...